Keros Therapeutics (KROS) Stock Statistics & Valuation Metrics

Keros Therapeutics has a market cap or net worth of $529.20M. The enterprise value is -$33.38M.

Keros Therapeutics has 30,466,068 shares outstanding. The number of shares has decreased by -2.65% in one year.

Keros Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -35.77%.

The current PE Ratio of Keros Therapeutics is 11.4. Keros Therapeutics’s PEG ratio is 0.82.

In the last 12 months, Keros Therapeutics had revenue of 3.55M and earned -187.35M in profits. Earnings per share was -5.00.

In the last 12 months, operating cash flow was 88.79M and capital expenditures -1.71M, giving a free cash flow of 87.08M billion.

Keros Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Keros Therapeutics upcoming earnings date is Mar 4, 2026, Before Open (Confirmed).

Keros Therapeutics as a current ratio of 21.45, with Debt / Equity ratio of 2.48%

In the past 12 months, Keros Therapeutics has paid 300.00K in taxes.

Keros Therapeutics EV to EBITDA ratio is -0.28, with an EV/FCF ratio of -0.32.

Keros Therapeutics has $693.47M in cash and marketable securities with $17.43M in debt, giving a net cash position of $676.04M billion.

Gross margin is 99.56%, with operating margin of -5938.96%, and net profit margin of -5277.55%.

The average price target for Keros Therapeutics is $20.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy